These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37528748)

  • 1. Why adverse outcome pathways need to be FAIR.
    Wittwehr C; Clerbaux LA; Edwards S; Angrish M; Mortensen H; Carusi A; Gromelski M; Lekka E; Virvilis V; Martens M; Bonino da Silva Santos LO; Nymark P
    ALTEX; 2024 Jan; 41(1):50-56. PubMed ID: 37528748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
    Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
    ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring a mechanism-based approach for the identification of endocrine disruptors using Adverse Outcome Pathways (AOPs) and New Approach Methodologies (NAMs) : A perfluorooctane sulfonic acid case study.
    Wiklund L; Pípal M; Weiss J; Beronius A
    Toxicology; 2024 May; 504():153794. PubMed ID: 38580097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semantic characterization of adverse outcome pathways.
    Wang RL
    Aquat Toxicol; 2020 May; 222():105478. PubMed ID: 32278258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps.
    Jaylet T; Coustillet T; Smith NM; Viviani B; Lindeman B; Vergauwen L; Myhre O; Yarar N; Gostner JM; Monfort-Lanzas P; Jornod F; Holbech H; Coumoul X; Sarigiannis DA; Antczak P; Bal-Price A; Fritsche E; Kuchovska E; Stratidakis AK; Barouki R; Kim MJ; Taboureau O; Wojewodzic MW; Knapen D; Audouze K
    Front Toxicol; 2024; 6():1285768. PubMed ID: 38523647
    [No Abstract]   [Full Text] [Related]  

  • 7. Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.
    Martens M; Verbruggen T; Nymark P; Grafström R; Burgoon LD; Aladjov H; Torres Andón F; Evelo CT; Willighagen EL
    Front Genet; 2018; 9():661. PubMed ID: 30622555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AOP Report: Inhibition of Chitin Synthase 1 Leading to Increased Mortality in Arthropods.
    Schmid S; Song Y; Tollefsen KE
    Environ Toxicol Chem; 2021 Aug; 40(8):2112-2120. PubMed ID: 33818824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of neurotoxicology (NT)/developmental neurotoxicology (DNT) adverse outcome pathways and key event linkages with in vitro DNT screening assays.
    Pitzer EM; Shafer TJ; Herr DW
    Neurotoxicology; 2023 Dec; 99():184-194. PubMed ID: 37866692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From papers to RDF-based integration of physicochemical data and adverse outcome pathways for nanomaterials.
    van Rijn JPM; Martens M; Ammar A; Cimpan MR; Fessard V; Hoet P; Jeliazkova N; Murugadoss S; Vinković Vrček I; Willighagen EL
    J Cheminform; 2024 May; 16(1):49. PubMed ID: 38693555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach.
    Saarimäki LA; Morikka J; Pavel A; Korpilähde S; Del Giudice G; Federico A; Fratello M; Serra A; Greco D
    Adv Sci (Weinh); 2023 Jan; 10(2):e2203984. PubMed ID: 36479815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse outcome pathways (AOPs) for radiation-induced reproductive effects in environmental species: state of science and identification of a consensus AOP network.
    Tollefsen KE; Alonzo F; Beresford NA; Brede DA; Dufourcq-Sekatcheff E; Gilbin R; Horemans N; Hurem S; Laloi P; Maremonti E; Oughton D; Simon O; Song Y; Wood MD; Xie L; Frelon S
    Int J Radiat Biol; 2022; 98(12):1816-1831. PubMed ID: 35976054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
    Bajard L; Adamovsky O; Audouze K; Baken K; Barouki R; Beltman JB; Beronius A; Bonefeld-Jørgensen EC; Cano-Sancho G; de Baat ML; Di Tillio F; Fernández MF; FitzGerald RE; Gundacker C; Hernández AF; Hilscherova K; Karakitsios S; Kuchovska E; Long M; Luijten M; Majid S; Marx-Stoelting P; Mustieles V; Negi CK; Sarigiannis D; Scholz S; Sovadinova I; Stierum R; Tanabe S; Tollefsen KE; van den Brand AD; Vogs C; Wielsøe M; Wittwehr C; Blaha L
    Environ Res; 2023 Jan; 217():114650. PubMed ID: 36309218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAIRification of nanosafety data to improve applicability of (Q)SAR approaches: A case study on
    Bossa C; Andreoli C; Bakker M; Barone F; De Angelis I; Jeliazkova N; Nymark P; Battistelli CL
    Comput Toxicol; 2021 Nov; 20():100190. PubMed ID: 34820591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical-induced liver cancer: an adverse outcome pathway perspective.
    Sanz-Serrano J; Callewaert E; De Boever S; Drees A; Verhoeven A; Vinken M
    Expert Opin Drug Saf; 2024 Apr; 23(4):425-438. PubMed ID: 38430529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
    Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
    ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A curated gene and biological system annotation of adverse outcome pathways related to human health.
    Saarimäki LA; Fratello M; Pavel A; Korpilähde S; Leppänen J; Serra A; Greco D
    Sci Data; 2023 Jun; 10(1):409. PubMed ID: 37355733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Raw Data to FAIR Data: The FAIRification Workflow for Health Research.
    Sinaci AA; Núñez-Benjumea FJ; Gencturk M; Jauer ML; Deserno T; Chronaki C; Cangioli G; Cavero-Barca C; Rodríguez-Pérez JM; Pérez-Pérez MM; Laleci Erturkmen GB; Hernández-Pérez T; Méndez-Rodríguez E; Parra-Calderón CL
    Methods Inf Med; 2020 Jun; 59(S 01):e21-e32. PubMed ID: 32620019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracting and Benchmarking Emerging Adverse Outcome Pathway Knowledge.
    Pollesch NL; Villeneuve DL; O'Brien JM
    Toxicol Sci; 2019 Apr; 168(2):349-364. PubMed ID: 30715536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.